Novocure (NVCR.O) said on Wednesday that its device met the main goal of a late-stage trial by slowing the progression of cancer to the brain in patients with a type of lung cancer, sending its shares up about 33% in before-the-bell trading.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,